[go: up one dir, main page]

AR102172A1 - Una composición farmacéutica bactericida y virucida - Google Patents

Una composición farmacéutica bactericida y virucida

Info

Publication number
AR102172A1
AR102172A1 ARP150103203A ARP150103203A AR102172A1 AR 102172 A1 AR102172 A1 AR 102172A1 AR P150103203 A ARP150103203 A AR P150103203A AR P150103203 A ARP150103203 A AR P150103203A AR 102172 A1 AR102172 A1 AR 102172A1
Authority
AR
Argentina
Prior art keywords
composition
ciprofloxacin
ampicillin
inflammatory
concentration
Prior art date
Application number
ARP150103203A
Other languages
English (en)
Inventor
Miguel Beltramo Dante
Gustavo Garro Ariel
Valeria Alasino Roxana
Javier Muoz Adrian
Alberto Argaars Luis
Original Assignee
Química Luar S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Química Luar S R L filed Critical Química Luar S R L
Priority to ARP150103203A priority Critical patent/AR102172A1/es
Priority to EP16853143.2A priority patent/EP3360547B1/en
Priority to PCT/ES2016/070702 priority patent/WO2017060550A1/es
Priority to PT168531432T priority patent/PT3360547T/pt
Priority to US15/766,029 priority patent/US10973787B2/en
Priority to BR112018006431-9A priority patent/BR112018006431A2/pt
Priority to PL16853143.2T priority patent/PL3360547T3/pl
Priority to ES16853143T priority patent/ES2928399T3/es
Publication of AR102172A1 publication Critical patent/AR102172A1/es
Priority to US17/199,822 priority patent/US11925612B2/en
Priority to US18/423,548 priority patent/US12171733B2/en
Priority to US18/946,091 priority patent/US20250213511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica bactericida y virucida, de aplicación sobre epitelios de tejidos como pulmonar, nasal y bucal, que comprende un anti-inflamatorio no esteroideo (AINE) en una concentración entre 5 y 500 mM solubilizado en solución salina hipertónica, aplicable a terapias de infecciones virales tipo Herpex simplex, para ser empleada como enjuague bactericida bucal, o bien para ser vehiculizada al pulmón mediante el uso de un nebulizador y proceso de elaboración. Reivindicación 6: La composición de la reivindicación 1 caracterizada porque dicho anti-inflamatorio no esteroideo es seleccionado del conjunto comprendido por Ibuprofeno, naproxeno, flurbiprofeno, ketoprofeno, diclofenac, diflunisal, etodolac, fenoprofen, indometacina, meclofenamato, mefenamic ácido, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, salicilatos acetilados, salicilatos no acetilados, y sus combinaciones. Reivindicación 16: La composición de la reivindicación 1 caracterizada porque dicha solución salina es hipertónica y comprende una concentración de entre 0,9 y 1,05 Molar de NaCl. Reivindicación 17: La composición de la reivindicación 1 caracterizada porque además comprende un agente anestésico. Reivindicación 18: La composición de la reivindicación 17 caracterizada porque dicho agente anestésico es seleccionado del conjunto comprendido por xilocaína, lidocaína, carticaína y mepivacaína. Reivindicación 24: La composición de la reivindicación 1 caracterizada porque además comprende antibióticos seleccionados del conjunto comprendido por colistimetato de sodio, tobramicina, ciprofloxacino, aztreonam lisina, levofloxacino, ciprofloxacino, fosfomicina, anfotericina B, vancomicina, gentamicina, ceftazidima, ampicilina, amikacina y sus mezclas.
ARP150103203A 2015-10-05 2015-10-05 Una composición farmacéutica bactericida y virucida AR102172A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ARP150103203A AR102172A1 (es) 2015-10-05 2015-10-05 Una composición farmacéutica bactericida y virucida
BR112018006431-9A BR112018006431A2 (pt) 2015-10-05 2016-10-04 uma composição farmacêutica bactericida e virucida
PCT/ES2016/070702 WO2017060550A1 (es) 2015-10-05 2016-10-04 Una composición farmacéutica bactericida y virucida
PT168531432T PT3360547T (pt) 2015-10-05 2016-10-04 Composição farmacêutica bactericida que compreende ibuprofeno
US15/766,029 US10973787B2 (en) 2015-10-05 2016-10-04 Bactericidal and virucidal pharmaceutical composition
EP16853143.2A EP3360547B1 (en) 2015-10-05 2016-10-04 Bactericidal pharmaceutical composition comprising ibuprofen
PL16853143.2T PL3360547T3 (pl) 2015-10-05 2016-10-04 Bakteriobójcza kompozycja farmaceutyczna zawierająca ibuprofen
ES16853143T ES2928399T3 (es) 2015-10-05 2016-10-04 Composición farmacéutica bactericida que comprende ibuprofeno
US17/199,822 US11925612B2 (en) 2015-10-05 2021-03-12 Bactericidal and virucidal pharmaceutical composition
US18/423,548 US12171733B2 (en) 2015-10-05 2024-01-26 Bactericidal and virucidal pharmaceutical composition
US18/946,091 US20250213511A1 (en) 2015-10-05 2024-11-13 Bactericidal and virucidal pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP150103203A AR102172A1 (es) 2015-10-05 2015-10-05 Una composición farmacéutica bactericida y virucida

Publications (1)

Publication Number Publication Date
AR102172A1 true AR102172A1 (es) 2017-02-08

Family

ID=58488060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103203A AR102172A1 (es) 2015-10-05 2015-10-05 Una composición farmacéutica bactericida y virucida

Country Status (8)

Country Link
US (4) US10973787B2 (es)
EP (1) EP3360547B1 (es)
AR (1) AR102172A1 (es)
BR (1) BR112018006431A2 (es)
ES (1) ES2928399T3 (es)
PL (1) PL3360547T3 (es)
PT (1) PT3360547T (es)
WO (1) WO2017060550A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102172A1 (es) 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
EP3946144A4 (en) * 2019-04-04 2023-01-04 The Texas A&M University System DELIVERY DEVICES FOR LOCALIZED DELIVERY OF ANTIMICROBIAL, ANTI-INFLAMMATORY AND ANTIOXIDANT AGENTS
US12324853B2 (en) * 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections
CN112843092B (zh) * 2021-01-20 2022-05-10 朱有建 免疫细胞在治疗疾病中的应用及其制备方法
AR127532A1 (es) * 2021-12-01 2024-02-07 Quim Luar S R L Composición farmacéutica que comprende ibuprofeno y arginina
WO2026011175A1 (en) * 2024-07-05 2026-01-08 Inspiranox Therapeutics Corporation Method for treating respiratory bacterial infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184013A (ja) * 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 点眼剤
EP1163906A3 (en) * 1994-03-15 2003-05-21 Senju Pharmaceutical Co., Ltd. Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US20030211173A1 (en) 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US7186186B2 (en) * 2005-01-22 2007-03-06 Takeo Imahata Game apparatus having a ball drop mechanism
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
CN101550119B (zh) 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
ES2607476T3 (es) * 2009-06-24 2017-03-31 Strategic Science & Technologies, Llc Composición tópica que contiene ibuprofeno
GB2477590A (en) 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
NZ588686A (en) * 2011-01-20 2013-07-26 Bayer New Zealand Ltd Injectable composition comprising an NSAID and an antibiotic in a non-aqueous solvent for treating a microbial infection in a mammary gland
CN102138893A (zh) * 2011-03-21 2011-08-03 陕西宏府怡悦制药有限公司 制备赖氨洛芬氯化钠注射液的工艺方法及其用途
JP5932993B2 (ja) * 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
AR102172A1 (es) * 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
EP3880173A1 (en) 2018-11-15 2021-09-22 Bluewillow Biologics, Inc. Nanoemulsion compositions having enhanced permeability
US12324853B2 (en) 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections

Also Published As

Publication number Publication date
US10973787B2 (en) 2021-04-13
BR112018006431A2 (pt) 2018-12-11
US20210275476A1 (en) 2021-09-09
WO2017060550A1 (es) 2017-04-13
EP3360547A1 (en) 2018-08-15
EP3360547B1 (en) 2022-07-13
US20180296509A1 (en) 2018-10-18
US20250213511A1 (en) 2025-07-03
ES2928399T3 (es) 2022-11-17
PT3360547T (pt) 2022-10-18
PL3360547T3 (pl) 2022-12-19
EP3360547A4 (en) 2019-08-21
US20240325332A1 (en) 2024-10-03
US11925612B2 (en) 2024-03-12
US12171733B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
AR102172A1 (es) Una composición farmacéutica bactericida y virucida
SV2018005778A (es) Derivados aromaticos de sulfonamida
ES2527994T3 (es) Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
BR112014027818A2 (pt) prevenção, ruptura e tratamento do biofilme com a lisina bacteriófaga
PE20100335A1 (es) Dispositivo de suministro de medicacion
PE20100152A1 (es) {5-[4-(6-CIANO-PIRIDIN-3-ILMETOXI)-FENIL]-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-2-IL}-AMIDA DEL ACIDO CICLOPROPANCARBOXILICO Y COMPOSICIONES QUE LO COMPRENDEN
BR112013026491A2 (pt) composição microbiocida, e, dispositivo de liberação de infusão intramamária
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
AR078310A1 (es) Composicion antimicrobiana
MX2018001584A (es) Composiciones de solución sólida para aines.
BR112016006589A2 (pt) composição, e composição de vacina
BR112012012486A2 (pt) "combinação para o tratamento de mocosite induzida por radiação ou quimioterapia"
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
MX392901B (es) Tratamiento que comprende la administracion oral o gastrica de edaravona
AR090569A1 (es) Agregados de nanoparticulas que contienen osteopontina y particulas que contienen calcio y/o estroncio
BR112017023250A2 (pt) sistema de liberação com base em bortezomibe
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
AR094976A1 (es) Composición dermatológica antimicrobiana tópica
UY30284A1 (es) Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3

Legal Events

Date Code Title Description
FG Grant, registration